Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) through its wholly-owned subsidiary Perma-Fix Medical Corporation has announced the successful validation of its technology involved in the production of Technetium-99m or Tc-99m. The company announced that the technology was validated after a series of rigorous tests. According to CEO of the subsidiary, Dr. Louis F. Centofanti, reaffirming and validation of their Tc-99m technology not only puts the business in the path of a promising market, but will also address the needs of the global Tc-99m supply chain. Besides offering a cheap and safe Tc-99m production process, the company announced their technology also meets and addresses key environmental concerns. The market in which Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) is vying with its latest radioisotope technology is projected to be worth more than $1.6 billion by 2017 in Europe alone. Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) shares after opening at $3.71 moved to $4.43 on last trade day and at the end of the day closed at $4.42. Company price to sales ratio in past twelve months was calculated as 0.57 and price to cash ratio as 501.80. Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) showed a positive weekly performance of 19.46%.
After surpassing its previously announced revenue objective in reporting of year 2013 financial results, GTT Communications Inc (NYSEMKT:GTT) promised to be more focused on expanding its technology offering. The company said that its cloud networking technology had greater opportunities in the world market. However, it needed to pair up or at least, following in the footsteps of industry giants. GTT Communications Inc (NYSEMKT:GTT) shares advanced 11.86% in last trading session and ended the day on $10.85.GTT return on equity ratio is recorded as -108.10% and its return on assets is -12.40%. GTT Communications Inc (NYSEMKT:GTT) yearly performance is 210.00%.
Cytokinetics, Incorporated (Nasdaq: CYTK) announced the initiation of an additional Phase I clinical trial of CK-2127107, a fast skeletal muscle troponin activator. The trial, called CY 5012, is a double-blind, randomized, placebo-controlled, parallel group study in which the primary objective is to assess the safety, tolerability, and pharmacokinetics of CK-2127107 following multiple ascending doses in healthy volunteers. The initiation of this clinical trial triggers a $2 million milestone payment from Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, “Astellas”) to Cytokinetics under the terms of the collaboration between the companies established in June 2013. Cytokinetics, Inc. (NASDAQ:CYTK) shares moved up 10.11% in last trading session and was closed at $9.37, while trading in range of $8.46-$9.39.Cytokinetics, Inc. (NASDAQ:CYTK) year to date performance is 44.15%.
Mandalay Digital Group Inc (NASDAQ:MNDL) , a leading provider of mobile technology solutions, summarized its fiscal 2015 guidance announced on a conference call and webcast on March 26, 2014, including anticipated 80% to 100% revenue growth over fiscal 2014. Mandalay Digital Group Inc (NASDAQ:MNDL) weekly performance is -1.22%. On last trading day company shares ended up $4.04. Mandalay Digital Group Inc (NASDAQ:MNDL) distance from 50-day simple moving average is 1.38%. Analysts mean target price for the company is $7.38.